Efficacy and safety of levocetirizine in persistent allergic rhinitis (PER) Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Efficacy of levocetirizine in perennial allergic rhinitis (PAR) as measured by the number of comfortable days Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Efficacy of ruzam in the treatment of patients with perennial allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004
Combination of montelukast and loratadine provides added benefit for relief of symptoms of seasonal allergic rhinitis (SAR) Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012
The efficacy of desloratadine in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: 330 Year: 2004
Evaluation of asthma patients using the control of allergic rhinitis and asthma test (CARAT) Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Effects of oromucosal immunotherapy (SLIT) in children with respiratory allergy Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
The specific methods of immunotherapy in treatment of the patients with allergic seasonal rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009